ClinicalTrials.gg
Active, not recruitingNCT06308159Updated Jun 15, 2026

An Open-label Study of a Gene Therapy Product (Vebeglogene Autotemcel) in Transfusion Dependent Beta-Thalassemia

A Phase 1/2 interventional study of Vebeglogene autotemcel in Beta-Thalassemia, sponsored by Lantu Biopharma. Active, not recruiting at 2 sites in China. Open to participants aged Up to 35 Years. Per ClinicalTrials.gov, last updated 2026-06-15.

Sponsored by Lantu Biopharma · Phase 1/2, Interventional, and Treatment

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1/2
Study type
Interventional
Enrollment
6
Allocation
Not applicable
Ages
Up to 35 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-21

Among 44 studies in beta-Thalassemia with a site in China — 20 open to participants now, 25 under way, 1 of them phase 3. beta-Thalassemia · China.

Planned enrollment
21st of 34
6 · median 10
Started
2024
with 10 others
Phase 1/2
5 of 44
1 open now
Primary completion
2027-08
later than 11 of 24 live
Registered
34th of 44
by date

Among the 44 studies in beta-Thalassemia with a site in China, this one is the 21st largest by planned enrollment of the 34 interventional ones that give a count, is one of 11 that started in 2024, is one of 5 in phase 1/2, reaches primary completion later than 11 of the 24 other live ones, and was the 34th registered.

beta-Thalassemia

295 studies on the registry are indexed under beta-Thalassemia; 70 are open to participants now.

Browse beta-Thalassemia studies →

Open to participants now

20 of the 44 studies in beta-Thalassemia with a site in China are open now. Recruiting first, the newest first:

15 more — sign in →

All 20 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 43 beta-Thalassemia studies recruiting now, 10 (23%) set no upper age limit and 31 (72%) stop at 75 or younger; 34 take children under 18; 6 take healthy volunteers.

This study: Up to 35 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 44 studies in beta-Thalassemia with a site in China, or all of them as a file.
02

Study summary

This is an interventional study to evaluate the safety and efficacy of autologous Hematopoietic Stem and Progenitor Cells (HSPCs) transduced with lentiviral vector encoding functional hemoglobin subunit beta (HBB) gene in patients with transfusion-dependent beta-thalassemia.

Read the detailed description

The participant's autologous HSPCs will be transduced with the self-inactivating lentiviral vector, carrying the functional HBB gene.

Study duration per participant is approximately 27 months including an approximately 30-day screening/baseline period, an approximately 60-day mobilization and product manufacture, an approximately 10-day myeloablative conditioning, 1 treatment day, and an approximately 24-month study observation period.

The endpoints will be used to assess the safety and efficacy profiles in patients with transfusion-dependent beta-thalassemia.

03

Conditions studied

  • Beta-Thalassemia

Browse trials for

04

Who can participate

Ages eligible
Up to 35 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Patients or parent(s)/legal guardian(s) willing and able to complete the process and comply with study procedures and visit schedules.
  • Diagnosis of beta-thalassemia and a history of RBCs transfusions.
  • Documented baseline, or pretransfusion, ≤7 g/dL.
  • Availability of an adequate and well-documented transfusion history.

Exclusion criteria

Exclusion Criteria:

  • Active bacterial, viral, fungal, or parasitic infection.
  • A white blood cell (WBC) counts\<3×10\^9/L, and/or counts\<100×10\^9/L not related to hypersplenism.
  • Uncorrected bleeding disorder.
  • Presence of severe diseases that judged not compatible with the study procedures, such as severe hepatic disease, kidney disease, lung disease, and/or cardiovascular disease.
  • Uncontrolled seizure disorder.
  • Any evidence of severe iron overload that, in the investigator's opinion, warrants exclusion.
  • Prior hematopoietic stem cell transplantation.
  • Prior receipt of gene therapy.
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Allogeneic and autologous transplant

Stem cell (bone marrow) transplants. Allogeneic uses cells from a donor; autologous uses your own cells, collected earlier and given back.

05

Study design

Phase
Phase 1 / Phase 2
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
6 participants (estimated)

Study arms

  • Experimental
    Vebeglogene autotemcel

    One-time infusion of≥5×10\^6/kg beta-globin lentiviral vector transduced HSPCs

    Drug: Vebeglogene autotemcel

Interventions

  • DrugVebeglogene autotemcel

    Autologous HSPCs transduced with self-inactivating lentiviral vector encoding functional HBB gene and resuspended in cryopreservative solution in the final immediate container for the intended medical use.

    Also known as: Beta-globin lentiviral vector transduced autologous HSPCs

06

What researchers measure

Primary outcomes

  1. Time and duration of the subject's hemoglobin (Hb)≥9.0 g/dL without receiving red blood cell infusion

    Time frame: From baseline to Month 24

Secondary outcomes

  1. The prevalence and severity of adverse events (AEs) and serious adverse events (SAEs)

    Participants are monitored for safety from baseline up to the end of the follow-up period.

    Time frame: From baseline to Month 24

  2. The reduction of red blood cells (RBCs) transfusion requirement after product infusion compared to previous transfusion records

    The annual number of RBCs transfusions prior to product infusion will be compared to the annual number of RBCs transfusions post-infusion, and the requirement reduction duration should be reported.

    Time frame: From infusion to Month 24

  3. Number of days required to achieve successful neutrophil and platelet engraftment

    Neutrophil engraftment is defined as the time to the first of 3 consecutive days of absolute neutrophil counts (ANC)≥0.5×10\^9/L post-infusion without transfusion. Platelet engraftment is defined as the time to the first of 3 consecutive days of platelet values≥20×10\^9/L post-infusion without transfusion.

    Time frame: From infusion to Month 24

  4. Vector copy number (VCN) in peripheral blood over time

    Quantification of the lentiviral vector copy number in individual peripheral blood cells will be conducted to measure the transduction of HSPCs.

    Time frame: From baseline to Month 24

07

Study locations

2 sites
  • 920th Hospital of Joint Logistics Support Force of People's Liberation Army of China
    Kunming, Yunnan 650100, China
  • Kunming Hope of Health Hospital
    Kunming, Yunnan 650200, China
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started May 2024 (actual). Primary completion is estimated for Aug 2027, 38 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 6, 2024
First posted
Mar 13, 2024
StartActual
May 11, 2024
Primary completionEst.
Aug 1, 2027
CompletionEst.
Aug 1, 2027
Last update
Jun 15, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 15, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT06308159
Lead sponsor
Lantu Biopharma
Responsible party
Sponsor
First posted
Mar 13, 2024
Start date
May 11, 2024
Primary completion
Aug 1, 2027 (estimated)
Completion
Aug 1, 2027 (estimated)
Last update
Jun 15, 2026

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Jun 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion